Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BIO Report: Attrition Higher For Novel Pain Candidates Than In Other Diseases, Funding Lacking

Executive Summary

A new report released during the BIO CEO conference shows novel pain therapy candidates face a high failure rate, which may help explain why smaller, privately held biotechs aren't very active in the space.

Advertisement

Related Content

What Does Rachel Sherman Think About Top FDA Regulatory Issues?
Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab
Opioid Treatments Could Get Survival Claim As US FDA Develops Protocol
Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market
Purdue Is Open For Business Deals And Shopping On Multiple Fronts
J&J Wins Nucynta ER Approval, Targets Chronic Pain Market
Pfizer to settle Celebrex and Bextra suits for $894 million

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100393

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel